Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash & Equivalents: 2020-2025

Historic Cash & Equivalents for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $91.6 million.

  • Xeris Biopharma Holdings' Cash & Equivalents rose 54.64% to $91.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.6 million, marking a year-over-year increase of 54.64%. This contributed to the annual value of $71.6 million for FY2024, which is 6.19% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Cash & Equivalents is $91.6 million, which was up 54.50% from $59.3 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Cash & Equivalents ranged from a high of $122.0 million in Q4 2022 and a low of $46.1 million during Q3 2023.
  • For the 3-year period, Xeris Biopharma Holdings' Cash & Equivalents averaged around $61.0 million, with its median value being $59.2 million (2024).
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Cash & Equivalents skyrocketed by 81.31% in 2022, and later plummeted by 51.57% in 2023.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Cash & Equivalents stood at $67.3 million in 2021, then spiked by 81.31% to $122.0 million in 2022, then plummeted by 44.70% to $67.4 million in 2023, then increased by 6.19% to $71.6 million in 2024, then surged by 54.64% to $91.6 million in 2025.
  • Its Cash & Equivalents was $91.6 million in Q3 2025, compared to $59.3 million in Q2 2025 and $58.4 million in Q1 2025.